Quick answer: latest quarter results, by ticker or company name

Reported Q: Q4 2024 Rev YoY: +12.4% EPS YoY: +79.5% Move: +5.09%

VistaGen Therapeutics Inc

VTGN

$0.601 5.09%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q4 2024

Published: Jun 11, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for VTGN

Reported

Report Date

Jun 11, 2024

Quarter Q4 2024

Revenue

197.30K

YoY: +12.4%

EPS

-0.35

YoY: +79.5%

Market Move

+5.09%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.20M up 12.4% year-over-year
EPS of $-0.35 increased by 79.5% from previous year
Gross margin of 100.0%
Net income of -9.52M
"Shawn Singh: "We are also exploring the therapeutic potential of itruvone, a differentiated therapy that can expedite relief for patients suffering from major depressive disorder......."" - Shawn Singh

VTGN

VistaGen Therapeutics Inc

Period Q4 2024

Currency USD

Report Type Quarterly Earnings

Generated Apr 1, 2026

Swipe to view all report sections

Executive Summary

In Q4 2024, VistaGen Therapeutics Inc reported a revenue of $197,300, a notable decline compared to previous quarters due to the transitional phase of clinical trials. The company achieved significant milestones, especially with its PALISADE-2 Phase 3 trial validation, marking a pioneering achievement in treating social anxiety disorder (SAD). However, losses continue to reflect the heavy R&D investments, totaling approximately $7.4 million in this quarter. Looking ahead, management is optimistic about advancing the PALISADE-3 trial and the potential market impact of their pipeline, while also addressing the ongoing cash burn and operational efficiency in this competitive biotech landscape.

Key Performance Indicators

Revenue

Increasing

197.30K

QoQ: -52.04% | YoY: 12.36%

Gross Profit

Increasing

197.30K

1.00% margin

QoQ: -52.04% | YoY: 12.36%

Operating Income

Increasing

-11.36M

QoQ: -44.08% | YoY: 7.19%

Net Income

Increasing

-9.52M

QoQ: -49.95% | YoY: 22.13%

EPS

Increasing

-0.35

QoQ: 18.60% | YoY: 79.53%

Revenue Trend

Margin Analysis

Financial Highlights

### Revenue Performance
- Revenue: $197,300 (down 52.04% QoQ), signaling transitions in trial phases rather than commercial traction.
- Gross Profit: $197,300.

### Profitability Metrics
- EBITDA: -$11,212,800, related to significant expenditures in clinical trials.
- Net Income: -$9,521,400 (Net Income Ratio: -48.26%).
- EPS: -$0.35, consistent with the loss trajectory but shows a year-over-year improvement in percentage terms.

### Cash Flow and Balance Sheet
- Cash at End of Period: $119,166,000, supporting ongoing operations.
- Total Liabilities: $9,367,000 against a strong equity base of $114,286,000.
- Current Ratio: 23.54, indicating substantial liquidity to cover short-term obligations.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	197.30K	12.36%	-52.04%
Gross Profit	197.30K	12.36%	-52.04%
Operating Income	-11.36M	7.19%	-44.08%
Net Income	-9.52M	22.13%	-49.95%
EPS	-0.35	79.53%	18.60%

Key Financial Ratios

Gross Profit Margin

Weak

1.00%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-57.57%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-48.26%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.08%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.08%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

23.54

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.02

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-3.83x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.28x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	0.24	-0.47	+23.7%	View
Q3 2025	0.23	-0.46	-43.1%	View
Q2 2025	0.18	-0.42	-34.2%	View
Q1 2025	0.08	-0.35	-52.5%	View
Q4 2024	0.20	-0.35	+12.4%	View

VTGN

VistaGen Therapeutics Inc

Q1 2026 Report

VistaGen Therapeutics Inc (VTGN) QQ1 2026 Earnings Analysis: PALISADE Phase III Progress, Open-Label Safety Signals, and Near-Term Catalysts...

Read full report

VTGN

VistaGen Therapeutics Inc

Q3 2025 Report

VistaGen Therapeutics Inc (VTGN) Q3 2025 Financial Results: Navigating Clinical Advancements and Financial Challenges...

Read full report

VTGN

VistaGen Therapeutics Inc

Q2 2025 Report

VistaGen Therapeutics Inc (VTGN) QQ2 2025 Financial Results Report: Navigating Through Growth Challenges...

Read full report

VTGN

VistaGen Therapeutics Inc

Q1 2025 Report

VistaGen Therapeutics Inc (VTGN) Q1 2025 Results Analysis: Progress in Pherine Drug Development and Financial Updates...

Read full report

VistaGen Therapeutics Inc (VTGN) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More VTGN Quarterly Reports

VTGN

VTGN

VTGN

VTGN

Q4 2024 Reports in Healthcare Sector

ALZN

Related Financial Data

Sector Analysis: Healthcare

VTGN Full Profile

VTGN Financial Statements

Earnings Calendar